Literature DB >> 25727260

The cost-effectiveness of harm reduction.

David P Wilson1, Braedon Donald2, Andrew J Shattock2, David Wilson3, Nicole Fraser-Hurt3.   

Abstract

HIV prevalence worldwide among people who inject drugs (PWID) is around 19%. Harm reduction for PWID includes needle-syringe programs (NSPs) and opioid substitution therapy (OST) but often coupled with antiretroviral therapy (ART) for people living with HIV. Numerous studies have examined the effectiveness of each harm reduction strategy. This commentary discusses the evidence of effectiveness of the packages of harm reduction services and their cost-effectiveness with respect to HIV-related outcomes as well as estimate resources required to meet global and regional coverage targets. NSPs have been shown to be safe and very effective in reducing HIV transmission in diverse settings; there are many historical and very recent examples in diverse settings where the absence of, or reduction in, NSPs have resulted in exploding HIV epidemics compared to controlled epidemics with NSP implementation. NSPs are relatively inexpensive to implement and highly cost-effective according to commonly used willingness-to-pay thresholds. There is strong evidence that substitution therapy is effective, reducing the risk of HIV acquisition by 54% on average among PWID. OST is relatively expensive to implement when only HIV outcomes are considered; other societal benefits substantially improve the cost-effectiveness ratios to be highly favourable. Many studies have shown that ART is cost-effective for keeping people alive but there is only weak supportive, but growing evidence, of the additional effectiveness and cost-effectiveness of ART as prevention among PWID. Packages of combined harm reduction approaches are highly likely to be more effective and cost-effective than partial approaches. The coverage of harm reduction programs remains extremely low across the world. The total annual costs of scaling up each of the harm reduction strategies from current coverage levels, by region, to meet WHO guideline coverage targets are high with ART greatest, followed by OST and then NSPs. But scale-up of all three approaches is essential. These interventions can be cost-effective by most thresholds in the short-term and cost-saving in the long-term.
Copyright © 2015 The Authors. Published by Elsevier B.V. All rights reserved.

Entities:  

Keywords:  Cost-effectiveness; HIV; Harm reduction; People who inject drugs

Mesh:

Substances:

Year:  2014        PMID: 25727260     DOI: 10.1016/j.drugpo.2014.11.007

Source DB:  PubMed          Journal:  Int J Drug Policy        ISSN: 0955-3959


  38 in total

Review 1.  Hepatitis C elimination among people who inject drugs: Challenges and recommendations for action within a health systems framework.

Authors:  Emma Day; Margaret Hellard; Carla Treloar; Julie Bruneau; Natasha K Martin; Anne Øvrehus; Olav Dalgard; Andrew Lloyd; John Dillon; Matt Hickman; Jude Byrne; Alain Litwin; Mojca Maticic; Philip Bruggmann; Havard Midgard; Brianna Norton; Stacey Trooskin; Jeffrey V Lazarus; Jason Grebely
Journal:  Liver Int       Date:  2018-09-22       Impact factor: 5.828

2.  The contribution of injection drug use to hepatitis C virus transmission globally, regionally, and at country level: a modelling study.

Authors:  Adam Trickey; Hannah Fraser; Aaron G Lim; Amy Peacock; Samantha Colledge; Josephine G Walker; Janni Leung; Jason Grebely; Sarah Larney; Natasha K Martin; Matthew Hickman; Louisa Degenhardt; Margaret T May; Peter Vickerman
Journal:  Lancet Gastroenterol Hepatol       Date:  2019-04-10

3.  Continuing Links Between Substance Use and HIV Highlight the Importance of Nursing Roles.

Authors:  Sherry Deren; Madeline Naegle; Holly Hagan; Danielle C Ompad
Journal:  J Assoc Nurses AIDS Care       Date:  2017-03-24       Impact factor: 1.354

Review 4.  Young Drug Users: a Vulnerable Population and an Underutilized Resource in HIV/HCV Prevention.

Authors:  Pedro Mateu-Gelabert; H Guarino; K Quinn; P Meylakhs; S Campos; A Meylakhs; D Berbesi; D Toro-Tobón; E Goodbody; D C Ompad; S R Friedman
Journal:  Curr HIV/AIDS Rep       Date:  2018-08       Impact factor: 5.071

Review 5.  Public health and international drug policy.

Authors:  Joanne Csete; Adeeba Kamarulzaman; Michel Kazatchkine; Frederick Altice; Marek Balicki; Julia Buxton; Javier Cepeda; Megan Comfort; Eric Goosby; João Goulão; Carl Hart; Thomas Kerr; Alejandro Madrazo Lajous; Stephen Lewis; Natasha Martin; Daniel Mejía; Adriana Camacho; David Mathieson; Isidore Obot; Adeolu Ogunrombi; Susan Sherman; Jack Stone; Nandini Vallath; Peter Vickerman; Tomáš Zábranský; Chris Beyrer
Journal:  Lancet       Date:  2016-03-24       Impact factor: 79.321

6.  Unmet service needs and barriers to care of individuals experiencing absolute homelessness in Edmonton, Canada: a cross-sectional survey.

Authors:  Sindi Addorisio; Mostafa Mamdouh Kamel; Jean Nicolas Westenberg; Amber Heyd; Tala Maragha; Mohammad Abusamak; T Cameron Wild; Kerry L Jang; R Michael Krausz
Journal:  Soc Psychiatry Psychiatr Epidemiol       Date:  2021-04-23       Impact factor: 4.328

7.  A no-brainer for ending AIDS: the case for a harm reduction decade.

Authors:  Catherine Cook; Rick Lines; David P Wilson
Journal:  J Int AIDS Soc       Date:  2016-04-20       Impact factor: 5.396

8.  The state of harm reduction in prisons in 30 European countries with a focus on people who inject drugs and infectious diseases.

Authors:  Heino Stöver; Anna Tarján; Gergely Horváth; Linda Montanari
Journal:  Harm Reduct J       Date:  2021-06-29

9.  Municipal police support for harm reduction services in officer-led referrals of people who inject drugs in Tijuana, Mexico.

Authors:  Pieter Baker; Jaime Arredondo; Annick Borquez; Erika Clairgue; Maria L Mittal; Mario Morales; Teresita Rocha-Jimenez; Richard Garfein; Eyal Oren; Eileen Pitpitan; Steffanie A Strathdee; Leo Beletsky; Javier A Cepeda
Journal:  Harm Reduct J       Date:  2021-07-26

10.  Effectiveness of the behavior change intervention to improve harm reduction self-efficacy among people who inject drugs in Thailand.

Authors:  Duangta Pawa; Chitlada Areesantichai
Journal:  Psychol Res Behav Manag       Date:  2016-09-06
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.